Review Papers Claim by Claim

What the paper does (visual summary)

• Catalogs the SAG superfamily: SAG1, SAG2 variants, SRS1–SRS8, BSR4, SAG3, SAG4A/B, SAG5A–C (Table 1 in paper) with GenBank accessions and stage‑expression notes.
• Provides phylogenetic analysis (ClustalW + PHYLIP neighbor‑joining) to show SAG1–SAG2 relationships and identifies orthologues in Neospora and Sarcocystis.
• Synthesizes functional data: antibody inhibition, chemical mutants, and targeted gene knockouts (SAG3 null, SAG1 null described) linking some SAGs to adhesion and immunopathology.
• Highlights major blindspots: incomplete expression/protein detection, unpublished data reliance, and strain bias (RH and a few isolates).

Lekutis et al., 2001 — SAG review

Key data extracted (from Table 1 and text) — plotted

Notes: counts approximate from Table 1 and text: many SRS entries clustered in the SAG1-like superfamily; SAG2 family reported separately with several short and long forms (SAG2A–E).

Functional evidence summarized (graphical)

Primary functional insights in the paper: (a) monoclonal antibodies against P30/SAG1 inhibit attachment to host cells (cited studies), (b) SAG3 knockout reduces host cell adhesion and virulence in mice, and (c) SAG1 knockout paradoxically increased in vitro invasion but reduced virulence via diminished immunopathology — interpreted as SAGs contributing both to adhesion and to immune modulation.

Lekutis et al., 2001 — functional summary

Critical strengths

• Comprehensive gene/protein catalog with GenBank accessions and stage annotations, enabling follow‑up genetic and proteomic work.
• Careful synthesis linking sequence families, phylogeny, stage expression and functional assays — useful roadmap for subsequent experimentalists and vaccine/diagnostic developers.
• Balanced interpretation: authors explicitly list limitations (antibody cross-reactivity, unpublished data, strain bias) and propose concrete next steps (multiple knockouts, stage comparisons).

Primary weaknesses / blindspots

1. Heavy reliance on antibody-based detection for many SAGs — cross-reactivity and epitope masking can mislead expression calls (acknowledged by authors).
2. Several entries and expression claims are described as "pers. commun." or unpublished — increases risk of unverified claims and selective reporting bias.
3. Functional genetics limited to only a few genes at that time (SAG1, SAG3); causality for most SAGs remains unproven in 2001.
4. Strain bias: most experimental data derive from lab strains (e.g., RH), limiting generalisability to other lineages — a concern given later discovery of strain-dependent virulence determinants (e.g., ROP5/ROP18 interplay) in the field.

Lekutis et al., 2001 — limitations

Context since 2001 (select citations that build on or test themes)

Post‑2001 literature has used SAG1 extensively in vaccine and diagnostic development; systematic reviews and experiments show SAG1 is immunodominant but stage‑restricted to tachyzoites and that multi‑antigen strategies perform better in many models — consistent with Lekutis et al.'s conclusion that multiple SAGs and stage coverage matter.

SAG1 vaccine systematic review

Quantitative paper‑scores (critical appraisal)

Where the paper could be disproven or revised (falsification tests)

1. Show that multiple putative SAG loci are non‑expressed at the protein level across strains and stages (mass spectrometry proteomics of tachyzoites, bradyzoites, sporozoites and merozoites) — would shrink the claimed superfamily.
2. Generate systematic multi‑gene knockouts (double/triple) and test invasion/virulence to see if loss of many SAGs yields no phenotype — would undercut proposed functional roles.
3. Perform cross-strain comparative genomics and expression (RNA-seq + proteomics) in wild isolates; if SAG repertoire is much smaller/less variable than claimed, reassessment needed.

Practical recommendations for researchers (actionable)

• Use modern deep proteomics (label-free LC‑MS/MS) across life stages and multiple isolates to validate which SAG open reading frames produce surface proteins.
• Perform CRISPR/Cas9 combinatorial knockouts and transcriptomic/proteomic compensation screens to test redundancy vs specialization.
• For vaccine/diagnostic work, favour multi‑antigen constructs (SAG1 + SRS/SAG2 or SRS67/SRS20A) and test across representative strain panels (Type I/II/III and non-canonical strains).

Glideosome and adhesins review

Concise final evaluation

Lekutis et al., 2001 provides a foundational, careful, and useful synthesis of the SAG superfamily at a time when sequence discovery outpaced functional testing. It precisely maps the research gaps and proposes next steps; later work (vaccines, diagnostics, genetics) has followed the roadmap. The principal limitation is the lack of functional validation for most SAG loci and reliance on antibody data and a few lab strains — problems that modern genomic/proteomic and CRISPR tools can and should rectify.

Lekutis et al., 2001 — concluding synthesis

Tools to continue this analysis

Would you like: (A) a reconciled, downloadable table of all SAG/SRS loci + GenBank accessions from the paper (ready for batch retrieval), (B) a phylogenetic reanalysis using all current ToxoDB sequences, or (C) an experimental plan (CRISPR multiplex knockout schedule) to test redundancy? Click an option to run a dedicated AI scientist agent.

Author review quick-links